Many viruses circulate seasonally, picking up as the weather cools in the fall and winter. So it’s true that fewer people get ...

Palantir Technologies soars with AI pivot, Pfizer holds steady, Caterpillar warns in contrasting earnings reports, offering investors a mix of optimism and caution in the tech, pharmaceutical, and ...

Company rebuilding following decline in demand for its covid products, slashing about €6.2bn from its spending and focusing ...

Pfizer's stock surges as the pharmaceutical company reports stronger-than-expected earnings, raised profit forecasts, and ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer reported a jump in second-quarter profits Tuesday behind higher sales of Covid-19 products and some other pharmaceuticals, while also benefiting from lower expenses.

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Now, it’s worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 a share to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the ...

Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter. The drugmaker now expects adjusted earnings per share between $2.90 and $3.10 compared ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Pfizer ( PFE) reported a beat in second quarter earnings Tuesday, and reaffirmed its 2025 guidance of between $61 to $64 ...